Danish Trade Distributors Stock News

Novo Nordisk (CPSE:NOVO B) has appointed Poul Weihrauch, CEO of Mars, as a board observer, with the intention to nominate him as a board member at the next AGM. The most recent AGM included key board elections, bringing in new directors and reshaping board committees. The company also released an update on its ongoing large scale share repurchase programme. Novo Nordisk, a major player in diabetes, obesity and chronic disease treatments, is adjusting its leadership structure at a time when...

Returns snapshot and recent performance A.P. Møller Mærsk (CPSE:MAERSK B) has delivered a 38.25% total return over the past year and 68.67% over the past 3 years, with a 9.56% gain year to date. Shorter term, the stock shows a 1.89% decline over the past day and a 4.37% decline over the past week, while the past month return stands at 2.68% and the past 3 months at 9.94%. See our latest analysis for A.P. Møller - Mærsk. The recent 1 week and 1 day share price declines sit against a stronger...

Recent share performance and business snapshot Ringkjøbing Landbobank (CPSE:RILBA) has seen its share price slip about 10% over the past month and roughly 2% over the past 3 months, inviting closer attention from income and value focused bank investors. The Danish lender focuses on private banking, mortgages, wealth management and broader financial services, all generated domestically, with reported revenue of DKK 4,155.8 million and net income of DKK 2,313.4 million, according to the latest...

Recent share performance and business profile Danske Bank (CPSE:DANSKE) shares have seen mixed returns recently, with a 5.3% decline over the past day and an 8.7% decline over the past month, following strong longer term gains. The bank has a market value of roughly DKK 245.1b and last closed at DKK 301.3. Reported annual revenue stands at DKK 56,546.0 and net income at DKK 23,037.0, with both metrics showing positive annual growth. Danske Bank offers a broad range of services across...

Investors who take an interest in ChemoMetec A/S ( CPH:CHEMM ) should definitely note that the Deputy Chairman, Hans...

Vestas Wind Systems (CPSE:VWS) is back in focus after announcing plans for a nacelle and hub factory in Scotland, which represents a more than €250 million offshore wind investment tied directly to UK auction outcomes. See our latest analysis for Vestas Wind Systems. The planned Scotland factory and recent wind turbine orders in France and Japan come as Vestas’ 7 day share price return of 12.7% contrasts with a negative year to date share price return and mixed multi year total shareholder...

Bavarian Nordic (CPSE:BAVA) has drawn renewed attention after recent trading, with the share price around Dkr191 following mixed short term returns and a 20.2% total return over the past year. See our latest analysis for Bavarian Nordic. The current Dkr191 share price comes after a modest 1 day share price decline and a small 30 day share price pullback, while the 1 year total shareholder return of 20.2% contrasts with weaker 3 and 5 year outcomes. This hints that momentum has recently been...

Why Carlsberg (CPSE:CARL B) is on investors’ radar Carlsberg (CPSE:CARL B) has drawn attention after a one‑month return of an 18% decline, alongside a past three‑month drop of 3.2%, prompting investors to reassess the brewer’s valuation and financial profile. See our latest analysis for Carlsberg. At a share price of DKK796.6, Carlsberg’s recent 18% one month share price decline sits alongside a 3.5% year to date share price fall and a 7.3% one year total shareholder return decline, pointing...

Novo Nordisk has received FDA approval for Awiqli®, the first once weekly basal insulin for adults with type 2 diabetes. The product introduces a new treatment option that reduces injection frequency compared with daily basal insulin regimens. This approval adds a new diabetes therapy alongside existing products and may influence how investors think about CPSE:NOVO B. Novo Nordisk, trading at DKK228.5 per share, has recently seen share price returns of 18.2% over five years, but a 54.5%...

A.P. Møller Mærsk (CPSE:MAERSK B) keeps Gulf food and medicine supply lines open by shifting to land-bridge routes through Saudi Arabia, Oman, and the UAE. The rerouting follows disruption to shipping in the Strait of Hormuz linked to the Iran conflict. Maersk uses cross border road and rail links to connect Gulf ports, reducing reliance on contested sea lanes. A.P. Møller Mærsk, via its ocean and logistics operations, sits at the center of container trade flows that connect producers and...

GN Store Nord stock performance snapshot GN Store Nord (CPSE:GN) has drawn investor attention after recent share price moves, with the stock up around 2% over the past day and about 5% over the past month, but showing weaker year to date and 1 year returns. See our latest analysis for GN Store Nord. That near term strength sits against a weaker backdrop, with a 90 day share price return of an 8.05% decline and a 1 year total shareholder return of a 14.18% loss. This suggests that recent...

GreenMobility A/S ( CPH:GREENM ) announced strong profits, but the stock was stagnant. Our analysis suggests that...

Last week's profit announcement from Fast Ejendom Danmark A/S ( CPH:FED ) was underwhelming for investors, despite...

Danske Bank shareholders approved all Board proposals at the annual general meeting, including major changes to the Board and capital structure. Martin Blessing was elected Chairman of the Board, marking a leadership change at CPSE:DANSKE. Shareholders backed a reduction in share capital and renewed capital authorisations that reshape the bank’s capital framework. Danske Bank, trading at DKK318.1, has seen a 44.3% return over the past year and a gain over five years of 262.3%. These moves...

AL Sydbank (CPSE:ALSYDB) has come into focus after recent share price pressure, including a 1 day return of 1.1% and an almost 10% decline over the past 3 months, prompting closer attention from investors. See our latest analysis for AL Sydbank. With the share price at DKK505.0, recent momentum has been soft, with a 30 day share price return of a 5.5% decline and a 90 day share price return of a 9.9% decline, set against a 1 year total shareholder return of 20% and a very large 5 year total...

Investors may be wondering whether Novo Nordisk’s current share price reflects its true worth, or if the recent weakness is creating a potential value opportunity. The stock last closed at DKK 240.30, with returns of 1.0% over 7 days, a 1.4% decline over 30 days, a 27.2% decline year to date, and a 48.6% decline over 1 year, while the 5-year return stands at 20.2%. These moves sit against a backdrop of ongoing attention on Novo Nordisk’s role in pharmaceuticals and biotech, including...

SP Group (CPSE:SPG) has wrapped up FY 2025 with fourth quarter revenue of DKK 826.4 million and basic EPS of DKK 7.40, alongside trailing twelve month revenue of DKK 2.95 billion and EPS of DKK 22.21 that reflect a 1.6% earnings increase over the past year. Over recent periods the company has seen quarterly revenue range from DKK 654.8 million to DKK 826.4 million, with basic EPS moving between DKK 4.12 and DKK 7.40. The trailing net profit margin has edged to 9% from 8.9% a year earlier,...

Rockwool (CPSE:ROCK B) has proposed at its upcoming April 15, 2026 AGM to cancel 4,346,560 repurchased class B shares, cutting nominal share capital and amending its Articles of Association. See our latest analysis for Rockwool. That capital reduction proposal comes after a weak stretch for the share price, with a 1 month share price return of a 20.19% decline and a 1 year total shareholder return of a 41.48% decline. This suggests momentum has been soft, even though the 3 year total...

As European markets navigate heightened uncertainty due to geopolitical tensions and soaring energy costs, the pan-European STOXX Europe 600 Index has seen a notable decline of 3.79%. Amidst these challenges, investors may find opportunities in stocks that appear undervalued based on their intrinsic value, offering potential for growth when market conditions stabilize.

FirstFarms FY 2025 Results: Margins Under Pressure As One Off Loss Hits Bottom Line FirstFarms (CPSE:FFARMS) has released its FY 2025 figures with third quarter revenue of DKK 91.7 million, basic EPS of DKK 0.03 on a trailing twelve month basis, and a trailing net profit margin of 0.09% compared with 2.8% a year earlier. Over recent periods, quarterly revenue has moved from DKK 107.4 million in Q3 2024 to DKK 91.7 million in Q3 2025, while basic EPS has swung between a loss of DKK 1.35 in Q1...

Wondering whether Jyske Bank at DKK 862.5 still offers value after a strong run, or if you might be late to the story? The share price has pulled back, with a 1.2% decline over the last week and a 10.1% decline over the last month. The 1 year return is 55.3% and the 5 year return is 215.1%. Recent coverage has focused on Jyske Bank's strong multi year share price performance, with attention on how the current pullback fits within a longer trend of gains such as the 99.1% 3 year return...

Earlier this week, United Biotechnology and Novo Nordisk reported phase 2 data from China showing that UBT251, a once-weekly triple-agonist for GLP-1, GIP and glucagon, reduced HbA1c and body weight more than semaglutide and placebo in people with type 2 diabetes over 24 weeks. This outperformance versus semaglutide adds a potentially important next-generation obesity and diabetes candidate to Novo Nordisk’s pipeline just as competition, pricing pressure and generic semaglutide emerge in key...

Zealand Pharma (CPSE:ZEAL) is setting up a major U.S. research hub in Cambridge, Massachusetts, focused on AI-driven drug discovery and automation. The new site will support work on hybrid therapies, including antibody peptide conjugates and siRNAs, alongside the company’s peptide heritage. The expansion is intended to plug Zealand Pharma directly into the Boston life sciences cluster, with implications for scientific capabilities and hiring. For investors tracking Zealand Pharma at a share...

Lu AF28996 data puts H. Lundbeck (CPSE:HLUN B) pipeline in focus Fresh Phase 1b data for Lundbeck's Lu AF28996 in advanced Parkinson's disease, combined with new insights on multiple system atrophy, has pushed the drugmaker's research pipeline and long term neurology focus back into the spotlight. See our latest analysis for H. Lundbeck. At a share price of DKK37.64, Lundbeck has a 90 day share price return of a 12.47% decline and a 1 year total shareholder return of a 0.50% decline, so...